Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2015 Publisher: MGI PHARMA LIMITED, Holborn Gate, 1st Floor, 330 High Holborn, London,WC1V 7QT, United Kingdom
GLIADEL 7.7 MG IMPLANT.
| Pharmaceutical Form |
|---|
|
Implant. Off-white to pale yellow flat discoid implant. |
Each implant contains 7.7 mg of carmustine.
For a full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Carmustine is a cell-cycle phase nonspecific antineoplastic agent of the nitrosourea type. As an alkylating agent, it can alkylate reactive sites on nucleoproteins, thus interfering with DNA and RNA synthesis and DNA repair. In addition, carmustine is known to carbamoylate lysine residues on proteins causing irreversible inactivation of enzymes including glutathione reductase. |
| List of Excipients |
|---|
|
Polifeprosan 20 |
GLIADEL Implant is available in a box containing eight implants. Each implant is individually packaged in two aluminium foil laminate sachets.
MGI PHARMA LIMITED, Holborn Gate, 1st Floor, 330 High Holborn, London,WC1V 7QT, United Kingdom
PL 18753/0001
Date of first authorisation: 28/05/1999
Date of last renewal: 10/12/2008
| Drug | Countries | |
|---|---|---|
| GLIADEL | Australia, Brazil, Spain, France, Hong Kong, Ireland, Israel, Japan, Singapore, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.